ArticleStatistics in medicine2026
Optimal Dynamic Treatment Regimes for High-Dimensional Accelerated Failure Time Model.
Article in Statistics in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The increasing prevalence of high-dimensional covariates presents a significant challenge to precision medicine. To overcome this, we propose a novel multi-stage optimal dynamic treatment regime method specifically designed for high-dimensional accelerated failure time models. Our approach, which aims to maximize individual survival time, employs backward induction with counterfactual survival times as the optimization objective at each stage. Parameter estimation leverages weighted counterfactual survival times to account for censoring, followed by the slope determination by analysis of residuals (SDAR) algorithm. Theoretical analysis guarantees exponential convergence with non-asymptotic error bounds under mild conditions. Simulation studies demonstrate a substantial improvement in survival time estimation, particularly under high censoring rates, compared to existing methods. We illustrate the practical utility of our method by applying it to a sepsis dataset, revealing clinically meaningful treatment recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.